Compare Essex Property Trust, Inc. (ESS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Organon & Co. Common Stock — how do they compare? Essex Property Trust, Inc. trades at $268.84 (market cap $17.47B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Essex Property Trust, Inc. is far larger — about 4.8× Organon & Co. Common Stock's market cap, and Essex Property Trust, Inc. pays the higher dividend (3.81%). Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 112 Days and Organon & Co. Common Stock for 0 Days on average.
| ESS | OGN | |
|---|---|---|
Market Cap | $17.47B | $3.62B |
Volume | 425,157 | 2,892,999 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $13.81 |
52-Week Low | $239.61 | $5.70 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $24.07B | $11.04B |
Dividend Yield | 3.81% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $269.37, down 0.38% with neutral technical signals. The company shows strong profitability with 67.9% gross margins and 21.48% net income, though recent earnings were mixed with Q2 2026 missing expectations. Revenue growth has been steady, reaching $1.89B in 2025. Analyst consensus is mixed with 38.3% buy ratings and a $300.77 price target, representing 11.7% upside. Recent news highlights strong Q2 results and legal resolution.
ESS offers solid fundamentals with premium valuation (P/E 42.35) and strong operational efficiency. Key risks include earnings volatility and high debt levels ($6.46B long-term). The stock presents opportunity from raised guidance and institutional interest, but requires monitoring of West Coast real estate market conditions and interest rate sensitivity.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
